Anlon Healthcare IPO: Key Things To Know About Pharmaceutical Company’s Public Issue

Anlon Healthcare Ltd IPO (Anlon Healthcare IPO) opened for subscription on August 26. The pharmaceutical product maker’s public issue saw strong investor interest on the first day of bidding. Here’s a look at some key things to know about Anlon Healthcare IPO before it opens for subscription:

Anlon Healthcare IPO GMP

Anlon Healthcare’s unlisted shares are commanding a grey market premium (GMP) ranging between Rs 5 and Rs 6 per share, according to multiple websites that monitor the movement of unlisted shares in the grey market. Given the GMP of Rs 6, the stock is expected to list at Rs 97 apiece, indicating a modest premium of 6.5 per cent.

Anlon Healthcare IPO Subscription

On the first day of subscription, Anlon Healthcare IPO was booked 1.69 times, cumulatively receiving applications for over 22.4 million shares compared to the 13.3 shares on offer. The retail investors led the demand for Anlon Healthcare’s shares, booking the issue 8.98 times. Qualified Institutional Buyers and Non-Institutional Investors booked their quota of 91 per cent and 71 per cent, respectively.

Anlon Healthcare IPO Offer Size, Listing Date, Price Band

Anlon Healthcare IPO issue size aggregates to Rs 121.03 crore. The public issue consists of a totally fresh issue of 13.3 million shares.

Anlon Healthcare IPO price band has been fixed at Rs 86 to Rs 91 per share. The minimum lot size for retail investors to apply for the Anlon Healthcare IPO has been set at 1 lot, consisting of 164 shares, aggregating to a minimum investment of Rs 14,924.

Anlon Healthcare IPO share allotment status is likely to be finalised on September 1. Once the share allotment status of Anlon Healthcare IPO is decided, successful bidders will receive shares of Anlon Healthcare in their demat accounts on September 2. Shares of Anlon Healthcare will tentatively list on the BSE and NSE. Anlon Healthcare's IPO listing date is September 3.

Anlon Healthcare: Key Financials

In the fiscal year ended March 31, 2025, Anlon Healthcare’s total income stood at Rs 120.46 crore, rising by over 80 per cent compared to Rs 66.69 crore in the preceding fiscal. The profit-after-tax of the company for the fiscal year under review grew by over 112 per cent to Rs 20.52 crore compared to Rs 9.66 crore in the preceding fiscal. Anlon Healthcare's net worth also increased by more than 282 per cent to Rs 80.42 crore in the fiscal year ended March 31, 2025, compared to Rs 21.03 crore in the financial year ended March 31, 2024.

Anlon Healthcare: Peers

According to Anlon Healthcare’s Red Herring Prospectus (RHP), the company has several peers such as Kronox Lab Sciences Ltd, Acutaas Chemicals Ltd, and Supriya Lifesciences Ltd.

Anlon Healthcare: Business Model

Anlon Healthcare Ltd operates as a chemical manufacturing company. The company is engaged in making pharmaceutical intermediates which are used as raw materials for making active pharmaceutical ingredients and active pharmaceutical ingredients. The pharmaceutical company’s product portfolio includes pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs, and ingredients for personal care and veterinary API.

Anlon Healthcare IPO: Risks And Strengths

Here’s a look at some of the key risks related to Anlon Healthcare’s business according to the company’s RHP:

• Anlon Healthcare disclosed in its RHP that its operations involve stringent quality specifications and regular customer audits; non-compliance with the specifications can lead to customer dissatisfaction or loss of business.

• The pharmaceutical company also mentioned in the RHP that it has not placed orders for equipment for the expansion of its manufacturing facility; further delay in the procurement process can lead to increased costs of commencing operations.

• The products made by the company are exposed to several risks like contamination, adulteration, and tampering during the process of production, which may adversely impact product quality, ultimately leading to reputational and financial loss.

Here’s a look at some of the key strengths of Anlon Healthcare according to the company’s RHP:

• The company claims to have a strong product portfolio comprising over 65 commercialised products and 28 products at the pilot stage, according to the RHP.

• Anlon Healthcare also claimed in its RHP that the company has a scalable business model and an established customer base.

• The pharmaceutical company also stated in its RHP that it has an in-house testing Quality Assurance / Quality Control for its product portfolio.

Anlon Healthcare IPO: Objective

Anlon Healthcare Ltd plans to use the money raised via the IPO for funding capital expenditure and working capital requirements. Other objectives include repayment of borrowings and funding Anlon Healthcare’s general corporate purposes.